Spine company launches strategic review after $3.6M loss

Advertisement

Xtant Medical Holdings is evaluating strategic alternatives after reporting a $3.6 million net loss in the third quarter of 2026, compared with net income of $1.3 million a year earlier.

The medical technology company’s revenue fell to $24.3 million from $33.3 million in the prior-year period. Xtant attributed the decline primarily to the loss of revenue from divested businesses and wound care licensing, according to a Nov. 16 news release. 

The company’s board is reviewing options including operational changes, financing, restructuring, partnerships and potential transactions. The review has no set completion date, and Xtant said it cannot guarantee a particular outcome.

Xtant also said it no longer expects to meet its full-year 2026 financial guidance after missing its projections for two consecutive quarters. The company will not issue revised guidance while the strategic review is underway.

Despite the overall revenue decline, Xtant’s biologics business generated $19.3 million in third-quarter revenue, up 13% year over year. The company ended the quarter with $7.8 million in cash and cash equivalents and $22 million in total indebtedness.

Advertisement

Next Up in Spine

Advertisement